TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Assessment of nutrition status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shear wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean frequency of circulating ALDHhiSSClow primitive progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction assessed by the Visual Individual Satisfaction Scale (VISS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of ipsilateral stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quality of life rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coronary revascularization outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: abdominal ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroscan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BUN, Cr level and estimated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete Blood Picture (WBCs, HB, Platelets)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arterial HbO2 saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between PET/CT and histopathological results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life measured by EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-related quality of life measured by NHP (Nottingham Health Profile)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in the cervical blood flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in the optic nerve sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in the cerebral oximeter values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in the Montreal cognitive assessment test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AGEs/RAGE ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-17 level in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-17 level in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacterial DNA profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of sick children receiving all medications indicated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of sick children correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental cost-effectiveness of eIMCI implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chronic Disease Adaptation Scale (CHAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance and Action Questionnaire-II Scale (AAQ-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Classification of perineal laceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: skeletal muscle oxygen saturation (TSI%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average rate of automatized artifacts rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of ruxolitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of adherence at individual and group level
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Days Prior to Elevation of Platelet Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pediatric neurodevelopmental outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pediatric behavioural outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of interdialytic weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: retinal nerve fibres layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of Sudden Cardiac Death (SCD)
Endpoint domain: Mortality/survival
Primary endpoint: Assessment of proprioception (deep sensation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of muscle tone (spasticity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body composition assessment (fat mass, visceral fat level, muscle tissue, fat free mass, water content in the body)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy of CT for coronary stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stiffness Area Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the SALT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Booking rate within 72 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient-Reported Outcomes Measurement Information System-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of perioperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Stages of Change for Dietary Fat Reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Oswestry LBP disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: bacterial composition difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Average Steps per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of All-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: rate of Major amputation
Endpoint domain: Adverse events/effects
Primary endpoint: rate of device success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events after administration of IMP
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients requiring escalation of oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from postoperative nausea degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from postoperative vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of cold application effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of MP delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEOWS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEWC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEWT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding or clinically relevant non-major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Anti-SARS-COV2 IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of Anti-SARS-COV2 IgG antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of low oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the adoption of outcome measures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effect of DAADs on COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial Interstitial Fluid Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differentiation of solid renal parenchyma masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Affect Assessments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in thiol disulfide values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal microbiome by next-generation sequencing (NGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal microbiome by Nugent scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BV recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of asynchrony events per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in interleukin-6 blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in tumor necrosis factor-alpha blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in interleukin-10 blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in c-reactive protein blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects receiving precision therapies providing biospecimens
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of subjects not receiving precision therapies and providing biospecimens
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RV fractional area change (RVFAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV Global Longitudinal strain (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse Device Effects (ADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Device Deficiency (DD)
Endpoint domain: Adverse events/effects
Primary endpoint: change in snoring duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with TI Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate of T cell lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Dental Caries (DMFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who completed the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postnatal growth retardation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement alteration of vaginal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcome of the variants of clinical concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical utility of analysing non-coding variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical and economic effects of rapid Whole Genome Sequencing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants with steroid-free clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of severity of ASD after intervention (DSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of severity of ASD after intervention (CARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in social interaction, adaptive behaviour, daily living skills (Vineland)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in social interaction, adaptive behaviour, daily living skills (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Feelings of stress and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and Specificity of the Classifier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correlation Between the Cognitive Wellness Score and the Neuropsychological Testing Battery Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Alteration of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who decide to enroll in clinical research
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: WOMAC index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Body Part Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in vaccine-specific antibody-secreting cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to guideline for cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Respiratory Muscle Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: surgery-associated inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgery-associated marker of senescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep behavior
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Frequency of unsafe sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Transplant list inclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with an abscopal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with treatment-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PROMIS-29 Mental (Psychosocial) Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: humoral immune response to Shingrix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence rate of any adverse reactions/events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence severity of any adverse reactions/events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of correct endobronchial intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent change in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiotherapy Mobile Acceptance Questionnaire (PMAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Residual concentration of ITK in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of musculoskeletal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of psychosocial wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of body weight (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of resting heart rate (beats per minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: detection sensitivity of genetic mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemineglect evaluation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom intensity sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abdominal pain intensity sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: inspiratory muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evaluation of frequency, seriousness and intensity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: MMSE global cognitive assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attention assessed by WAIS digit spans
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Executive functions assessed by the TMT A AND B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gastrointestinal Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in Corpus Callosum Myelin Water Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Corpus Callosum T1 Relaxation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Corpus Callosum UTE Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypotension events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myeloproliferative Neoplasm-10 Total Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: occurrence of vaccine-associated serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of subjects achieving a serum HAI antibody titer of 1:40 or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of subjects with 4-fold or greater hemagglutination inhibition (HAI) antibody titer increases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morphological characters of choroidal neovascular membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraclass correlation coefficient (ICC) between BePoW measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient r between raw goniometric measurements and BePoW measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of LY3871801
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3871801
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to exercise limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Lesions With BCC Histological Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Treatment Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Impact of MBQR intervention on HIV/STI testing: home testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Impact of MBQR intervention on sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Acceptability of online MBQR as measured by the Client Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of a stable epithelium on cornea and absence of conjunctivalization in the visual axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Extent of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Efficacy of experimental treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of experimental treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cross-sectional area of the antrum (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predicted volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Observed volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hepatitis B Surface Antigen (HBsAg) Seroclearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Longitudinal change in tau PET uptake values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise load end heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes